Funder: National Institutes of Health

Due Dates: June 20, 2025 (New/Renewal/Resubmission/Revision) | February 20, 2026 (New/Renewal/Resubmission/Revision) | June 22, 2026 (New/Renewal/Resubmission/Revision)

Funding Amounts: Up to $700,000 total costs/year (Phase I, max 2 years); up to $1,500,000 total costs/year (Phase II, max 3 years); max project period 4 years.

Summary: Supports rigorous analytical validation of biomarker detection methods for neurological or neuromuscular disorders, enabling reproducibility and accuracy per FDA guidelines.

Key Information: Only U.S. small businesses are eligible; clinical trial is optional; limited submission—see eligibility details.